Lonza signs exclusive agreement with Index Ventures
Five year agreement includes all companies where Index Ventures will be the majority shareholder
Over the course of the agreement, additional development and manufacturing projects will be added to the product list, as future investments are made by Index.
“This agreement shows that Lonza’s value to a company’s product development pipeline is being recognized more widely by investors in biotech companies,” said Dr. Stephan Kutzer, COO Lonza Pharma&Biotech. “This multi-product agreement demonstrates Lonza’s ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.”
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.